Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery
Predictive Oncology Inc. (NASDAQ: POAI) has announced successful study results demonstrating the long-term stability and viability of over 150,000 cryopreserved patient tumor samples in its proprietary biobank. The study showed 100% concordance in drug response results between original fresh patient sample testing and long-term cryogenically stored tumor material, some preserved for up to 16 years.
This validation is important for predicting patient outcomes, guiding personalized therapies, target validation, and in silico modeling of drug-tumor responses. The company's biobank, containing 150,000+ tumor specimens, 200,000+ pathology slides, and 20 years of actionable data, positions Predictive Oncology as a key player in AI-driven drug discovery. The global biospecimen market, valued at $4.4 billion in 2023, is expected to reach $11.7 billion by 2031, growing at a CAGR of over 13%.
Predictive Oncology Inc. (NASDAQ: POAI) ha annunciato i risultati di uno studio che dimostrano la stabilità e la vitalità a lungo termine di oltre 150.000 campioni di tumori congelati di pazienti nel suo biobanco proprietario. Lo studio ha mostrato una concordanza del 100% nei risultati di risposta ai farmaci tra il test originale su campioni freschi di pazienti e il materiale tumorale conservato a lungo termine a temperature criogeniche, alcuni dei quali sono stati conservati per un massimo di 16 anni.
Questa validazione è importante per prevedere gli esiti dei pazienti, guidare le terapie personalizzate, la validazione degli obiettivi e la modellazione in silico delle risposte ai farmaci sui tumori. Il biobanco dell'azienda, contenente oltre 150.000 campioni di tumori, oltre 200.000 vetrini patologici e 20 anni di dati utili, posiziona Predictive Oncology come un attore chiave nella scoperta di farmaci guidata dall'IA. Il mercato globale dei biospecimens, valutato a 4,4 miliardi di dollari nel 2023, è previsto crescere fino a 11,7 miliardi di dollari entro il 2031, con un tasso di crescita annuale composto (CAGR) superiore al 13%.
Predictive Oncology Inc. (NASDAQ: POAI) ha anunciado resultados exitosos de un estudio que demuestran la estabilidad y viabilidad a largo plazo de más de 150,000 muestras de tumores de pacientes criopreservadas en su biobanco propietario. El estudio mostró una concordancia del 100% en los resultados de respuesta a fármacos entre las pruebas de muestras frescas de pacientes originales y el material tumoral almacenado a largo plazo a temperaturas criogénicas, algunos conservados por hasta 16 años.
Esta validación es importante para predecir los resultados de los pacientes, guiar las terapias personalizadas, la validación de objetivos y la modelación in silico de las respuestas de los fármacos a los tumores. El biobanco de la empresa, que contiene más de 150,000 especímenes tumorales, más de 200,000 diapositivas patológicas y 20 años de datos accionables, posiciona a Predictive Oncology como un actor clave en la descubrimiento de fármacos impulsado por IA. Se espera que el mercado global de biospecímenes, valorado en $4.4 mil millones en 2023, alcance los $11.7 mil millones para 2031, creciendo a una tasa compuesta anual (CAGR) de más del 13%.
Predictive Oncology Inc. (NASDAQ: POAI)는 자체 생물은행에서 150,000개 이상의 냉동 환자 종양 샘플의 장기 안정성 및 생존 가능성을 보여주는 성공적인 연구 결과를 발표했습니다. 연구 결과는 원래 신선한 환자 샘플 테스트와 장기적으로 냉동 보관된 종양 재료 간의 약물 반응 결과가 100% 일치함을 보여주었으며, 이 중 일부는 최대 16년 동안 보존되었습니다.
이 검증은 환자 결과 예측, 개인 맞춤 치료 안내, 타겟 검증, 약물-종양 반응의 기계 모델링에 중요합니다. 150,000개 이상의 종양 샘플, 200,000개 이상의 병리 슬라이드, 20년의 유용한 데이터를 포함하는 회사의 생물은행은 Predictive Oncology를 AI 기반 약물 발견의 주요 플레이어로 위치시킵니다. 2023년 44억 달러로 평가된 글로벌 바이오샘플 시장은 2031년까지 117억 달러에 이를 것으로 예상되며, 연평균 성장률(CAGR)이 13%를 초과할 것으로 보입니다.
Predictive Oncology Inc. (NASDAQ: POAI) a annoncé les résultats d'une étude réussie démontrant la stabilité et la viabilité à long terme de plus de 150 000 échantillons de tumeurs de patients cryoconservés dans sa biobanque propriétaire. L'étude a montré une concordance de 100% dans les résultats de réponse aux médicaments entre les tests d'échantillons frais de patients originaux et le matériel tumoral stocké à long terme à des températures cryogéniques, certains préservés pendant jusqu'à 16 ans.
Cette validation est importante pour prédire les résultats des patients, guider les thérapies personnalisées, valider les cibles et modéliser in silico les réponses aux médicaments-tumeurs. La biobanque de l'entreprise, contenant plus de 150 000 spécimens tumoraux, plus de 200 000 lames pathologiques et 20 ans de données exploitables, positionne Predictive Oncology comme un acteur clé dans la découverte de médicaments pilotée par l'IA. Le marché mondial des biospecimens, évalué à 4,4 milliards de dollars en 2023, devrait atteindre 11,7 milliards de dollars d'ici 2031, avec un taux de croissance annuel composé (CAGR) supérieur à 13 %.
Predictive Oncology Inc. (NASDAQ: POAI) hat erfolgreiche Studienergebnisse angekündigt, die die langfristige Stabilität und Lebensfähigkeit von über 150.000 kryokonservierten Tumorproben von Patienten in seinem proprietären Biobanken zeigen. Die Studie zeigte eine 100%ige Übereinstimmung bei den Ergebnissen der Medikamentenreaktion zwischen den Tests von frischen Originalpatientenproben und dem langfristig kryogenisch gespeicherten Tumormaterial, einige davon seit bis zu 16 Jahren aufbewahrt.
Diese Validierung ist wichtig für die Vorhersage von Patientenausgängen, die Anleitung personalisierter Therapien, die Validierung von Targets und die In-silico-Modellierung von Arzneimittel-Tumor-Reaktionen. Das Biobank des Unternehmens, das über 150.000 Tumorproben, über 200.000 pathologische Schnitte und 20 Jahre umsetzbare Daten enthält, positioniert Predictive Oncology als einen Schlüsselspieler in KI-gesteuerter Arzneimittelforschung. Der globale Markt für Biospecimen, der 2023 auf 4,4 Milliarden US-Dollar geschätzt wird, wird voraussichtlich bis 2031 auf 11,7 Milliarden US-Dollar anwachsen und mit einer jährlichen Wachstumsrate (CAGR) von über 13% wachsen.
- 100% concordance in drug response results between fresh and long-term stored samples
- Validated long-term viability of 150,000+ tumor specimens in proprietary biobank
- 20 years of longitudinal patient and drug response data
- Unique position in enabling drug developers to query patient responses before clinical trials
- Capability to build models for accurately predicting patient outcomes
- None.
This study by Predictive Oncology is a significant breakthrough in biobanking and drug discovery. The demonstration of 100% concordance in drug response results between fresh samples and those cryopreserved for up to 16 years is remarkable. This validates the integrity of their 150,000+ tumor specimen biobank, enhancing its value for pharmaceutical research.
The ability to reliably predict patient outcomes using historical samples is a game-changer for personalized medicine and drug development. It allows for more accurate in silico modeling of drug-tumor responses, potentially reducing the time and cost of bringing new cancer treatments to market. This could accelerate the drug discovery process and improve the success rate of clinical trials.
However, it's important to note that while this study focused on ovarian tumor samples, further validation across other cancer types would strengthen these findings. Overall, this development positions Predictive Oncology as a valuable partner for pharmaceutical companies in oncology drug discovery.
From a financial perspective, this development significantly enhances Predictive Oncology's market position. The global biospecimen market, valued at
The company's unique assets - 150,000+ tumor specimens, 200,000 pathology slides and 20 years of drug response data - create a high barrier to entry for competitors. This could lead to increased partnerships with pharmaceutical companies, potentially boosting POAI's revenue streams.
However, investors should consider that while this technology is promising, its full commercial impact may take time to materialize. The company's ability to monetize this asset effectively and manage operational costs will be important for future financial performance. Keep an eye on upcoming quarterly reports for signs of increased partnership deals or revenue growth.
Study further validates highly reproducible drug response data. Enables AI platform to model and predict patient outcomes on historical samples
Global biospecimen market valued at
PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced the results of a successful study that demonstrates the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples stored within the Company’s proprietary biobank.
Importantly, with more than 20 years of longitudinal patient and drug response data, the study demonstrated that the samples stored in the biobank continue to produce drug response data that is consistent with their original clinical testing results. This is critical for predicting outcomes, most notably overall survival (OS), for guiding personalized therapies, target validation, and in silico modeling of drug-tumor responses.
To successfully demonstrate the reproducibility of drug response results for these biobank samples, a comparative study was executed using previously generated drug responses across a subset of patient ovarian tumor samples maintained in the Company’s biobank. These samples had originally been tested and cryopreserved between 2008 and 2016.
Concordance of drug response results between the original fresh patient sample testing and long-term cryogenically stored tumor material from the same patient was
“We are extremely pleased with the results of this study, which demonstrates that even after an extended period of time – some as long as 16 years – the samples cryopreserved in our biobank remain viable and able to deliver the same drug response data as when originally tested,” said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery at Predictive Oncology. “This not only validates the utility of our biobank, but also the strength and reliability of the drug response data that we compiled over those many years. We are uniquely positioned to enable drug developers to query patient responses to their drug candidates, accounting for real-world patient heterogeneity, and to validate targets and biomarkers long before human clinical trials commence.”
“Our biobank of more than 150,000 tumor specimens, 200,000 pathology slides, and 20 years of actionable drug and tumor response data represent key assets that are unique to Predictive Oncology,” stated Raymond Vennare, Chief Executive Officer of Predictive Oncology. “With these capabilities, we can build models capable of accurately predicting patient outcomes, allowing us to play a key role in guiding personalized therapies, and discovering novel biomarkers. The results of this study demonstrate the long-term viability of these tumor samples, underscoring its value not only to Predictive Oncology, but our drug developer partners as well.”
Predictive Oncology also announced today the release of a new white paper that discusses this study, and the importance of tumor sample viability, in greater detail. The white paper can be accessed at: https://predictive-oncology.com/blog/reproducible/
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s proprietary AI/ML platform has been scientifically validated to predict with
Investor Relations Contact
Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements.
___________________________________
1 https://www.biospace.com/biospecimen-contract-research-services-market-worth-usd-11-70-billion-to-2031
FAQ
What were the results of Predictive Oncology's (POAI) biobank stability study?
How does the biobank study impact Predictive Oncology's (POAI) drug discovery capabilities?
What is the size and scope of Predictive Oncology's (POAI) biobank as of August 2024?
What is the projected growth of the global biospecimen market according to Predictive Oncology's (POAI) press release?
